ProteoDesign has closed a round of financing lead by Caixa Capital Risc. These funds will allow ProteoDesign to complete the first phase of its ADC development program. ”la Caixa” participates in this operation through the Caixa Innvierte BioMed II fund.
Archives
Recent Posts
- ProteoDesign secures a 1.7M€ financing round led by Caixa Capital Risc
- ProteoDesign to attend BIO-Europe Spring 2018 in Amsterdam
- ProteoDesign’s fight against cancer featured in “ARA” newspaper
- Miquel Vila-Perelló interviewed by the CataloniaBio newsletter
- ProteoDesign leads the ToxAb consortium awarded with a “RETOS de Colaboración” grant